Enhanced bioavailability and short-term safety of a micellar green tea extract formulation co-delivered with N-acetylcysteine: a randomized crossover study in healthy adults.

Introduction: Green tea catechins, particularly epigallocatechin gallate (EGCG), the principal polyphenol in green tea ( Methods: The study comprised two parts: a randomized, double-blind, crossover pharmacokinetic trial in 16 healthy adults comparing LGT 330 mg with SGT 330 mg and SGT 660 mg, followed by a 30-day open-label, single-arm safety study evaluating LGT 1,320 mg/day in 13 participants. Results: For EGCG, LGT significantly increased baseline-adjusted systemic exposure compared with dose-matched SGT, producing a 4.2-fold higher iAUC₀-₂₄ (1857 ± 1,479 vs. 443 ± 1,570 ng·h/mL; Conclusion: These findings demonstrate that LGT significantly enhances systemic EGCG exposure while remaining well tolerated for over 30 days in healthy adults. Larger and longer-term studies are warranted to determine whether improved EGCG exposure translates into clinically meaningful health benefits. Clinical trial registration: https://clinicaltrials.gov/, registration number NCT06971536.